InstitutionMD Anderson
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wang ML, Le Gouill S, Dreyling M. Treatment of Mantle-Cell Lymphoma. Reply. N Engl J Med. 2022 09 22; 387(12):1148. PMID: 36130010.
    2. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415. PMID: 35074072.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Wang M, Jain P, Chi TL, Chen SE, Heimberger A, Weathers SP, Zheng L, Rao AV, Rossi JM. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J Immunother Cancer. 2020 10; 8(2). PMID: 33067318; PMCID: PMC7570235.
      Citations: 2     Fields:    Translation:Humans
    4. Wang M, Rule S, Goy A, Smith SD, Doorduijn JK, Lamy T, Shah B, Davies A, Eek R, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Dlugosz-Danecka M, Zinzani PL, Casasnovas O, Damaj G, Morschhauser F, Panizo C, Dupuis J. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019 11; 33(11):2762-2766. PMID: 31558766.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    5. Ahmed M, Lorence E, Wang J, Jung D, Zhang L, Nomie K, Wang M. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma. Sci Signal. 2019 02 05; 12(567). PMID: 30723172.
      Citations: 3     Fields:    Translation:HumansCells
    6. Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980. PMID: 29666304.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    7. Wang M, Rule S, Goy A, Casasnovas O, Smith SD, Doorduijn J, Lamy T, Shah B, Davies A, Eek R, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W, Zinzani PL, Damaj G, Morschhauser F, Panizo C, Dupuis J. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018 02 17; 391(10121):659-667. PMID: 29241979; PMCID: PMC7864374.
      Citations: 104     Fields:    Translation:HumansCTClinical Trials
    8. Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Martin P, Bravo MC. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017 11 02; 10(1):171. PMID: 29096668; PMCID: PMC5668956.
      Citations: 12     Fields:    Translation:Humans
    9. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56. PMID: 26640039.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    10. Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst. 2016 Mar; 108(3). PMID: 26582244; PMCID: PMC6280981.
      Citations: 15     Fields:    Translation:Humans
    11. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 06; 126(6):739-45. PMID: 26059948; PMCID: PMC4528064.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    12. Wang Y, Zhang LL, Champlin RE, Wang ML. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. 2015 May; 97(5):455-68. PMID: 25669675.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    13. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant. 2015 May; 50(5):668-72. PMID: 25730192.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    14. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-1179. PMID: 25712454.
      Citations: 39     Fields:    Translation:Humans
    15. Hao C, Wang L, Peng S, Cao M, Li H, Hu J, Huang X, Liu W, Zhang H, Wu S, Pataer A, Heymach JV, Eterovic AK, Zhang Q, Shaw KR, Chen K, Futreal A, Wang M, Hofstetter W, Mehran R, Rice D, Roth JA, Sepesi B, Swisher SG, Vaporciyan A, Walsh GL, Johnson FM, Fang B. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185. PMID: 25444907; PMCID: PMC4301580.
      Citations: 52     Fields:    Translation:HumansAnimals
    16. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8. PMID: 25439689; PMCID: PMC4370362.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    17. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8. PMID: 25445468; PMCID: PMC4344896.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    18. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9). PMID: 25214559; PMCID: PMC4200057.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    19. Haque W, Voong KR, Shihadeh F, Arzu I, Pinnix C, Mazloom A, Medeiros LJ, Romaguera J, Rodriguez A, Wang M, Allen P, Dabaja B. Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):474-9. PMID: 25108680.
      Citations: 7     Fields:    Translation:Humans
    20. Chen Y, Wang M, Romaguera J. Current regimens and novel agents for mantle cell lymphoma. Br J Haematol. 2014 Oct; 167(1):3-18. PMID: 24974852.
      Citations: 9     Fields:    Translation:Humans
    21. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901. PMID: 24943107.
      Citations: 105     Fields:    Translation:Humans
    22. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014 Jul 29; 111(3):628-36. PMID: 24921909; PMCID: PMC4119980.
      Citations: 24     Fields:    Translation:Humans
    23. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant. 2014 Aug; 49(8):1036-41. PMID: 24887378.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    24. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41. PMID: 24886772; PMCID: PMC4038108.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    25. Pham LV, Vang MT, Tamayo AT, Lu G, Challagundla P, Jorgensen JL, Rollo AA, Ou Z, Zhang L, Wang M, Ford RJ. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma. 2015 Jan; 56(1):186-93. PMID: 24611650; PMCID: PMC5779854.
      Citations: 6     Fields:    Translation:HumansCells
    26. Wang M, Popplewell LL, Collins RH, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014 May; 165(4):510-8. PMID: 24579926.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    27. Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014 Apr 03; 123(14):2204-8. PMID: 24425802; PMCID: PMC3975258.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    28. Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014 Apr; 93(4):541-56. PMID: 24375125.
      Citations: 10     Fields:    Translation:HumansAnimals
    29. Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92. PMID: 24326130; PMCID: PMC3878866.
      Citations: 11     Fields:    Translation:HumansCells
    30. Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant. 2014 Mar; 49(3):422-5. PMID: 24317125.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    31. Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781. PMID: 24204673; PMCID: PMC3800010.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    32. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20. PMID: 24117234; PMCID: PMC5278952.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    33. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31; 122(18):3122-8. PMID: 24014245; PMCID: PMC3814729.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    34. Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther. 2013 Nov; 12(11):2494-504. PMID: 23990113.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    35. Axelrod M, Ou Z, Brett LK, Zhang L, Lopez ER, Tamayo AT, Gordon V, Ford RJ, Williams ME, Pham LV, Weber MJ, Wang ML. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia. 2014 Feb; 28(2):407-10. PMID: 23979520; PMCID: PMC3918872.
      Citations: 16     Fields:    Translation:HumansCells
    36. Desai M, Newberry KJ, Romaguera J, Zhang L, Ou Z, Wang M. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol. 2013 Aug 02; 6:55. PMID: 23915913; PMCID: PMC3735404.
      Citations: 6     Fields:    Translation:HumansAnimals
    37. Chen Z, Pittman EF, Romaguera J, Fayad L, Wang M, Neelapu SS, McLaughlin P, Kwak L, McCarty N. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PLoS One. 2013; 8(8):e69126. PMID: 23936317; PMCID: PMC3732253.
      Citations: 16     Fields:    Translation:HumansCells
    38. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 08; 369(6):507-16. PMID: 23782157; PMCID: PMC4513941.
      Citations: 553     Fields:    Translation:HumansCTClinical Trials
    39. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014 Feb; 28(2):373-83. PMID: 23760401; PMCID: PMC3874423.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    40. Zhang L, Newberry KJ, Wang M. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. Expert Rev Clin Immunol. 2013 Jun; 9(6):495-7. PMID: 23730878.
      Citations:    Fields:    Translation:HumansAnimals
    41. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6. PMID: 23670297; PMCID: PMC3865533.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    42. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013 Aug; 41(8):719-30. PMID: 23648290; PMCID: PMC3769691.
      Citations: 8     Fields:    Translation:HumansCells
    43. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9. PMID: 23545991.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    44. Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Winter JN, Go RS, Piris MA, Wu L, Wang M, Ramos KS, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 30; 121(22):4529-40. PMID: 23515929; PMCID: PMC3668486.
      Citations: 16     Fields:    Translation:HumansCells
    45. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56. PMID: 23447001; PMCID: PMC4149337.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    46. Alexanian R, Delasalle K, Wang M. High frequencies of response after limited primary therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):119-22. PMID: 23260599.
      Citations:    Fields:    Translation:Humans
    47. Fu W, Delasalle K, Wang J, Song S, Hou J, Alexanian R, Wang M. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol. 2012 Dec; 35(6):562-5. PMID: 21694573.
      Citations: 5     Fields:    Translation:Humans
    48. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013 Jan; 41(1):67-78.e4. PMID: 22986101.
      Citations: 63     Fields:    Translation:HumansAnimalsCells
    49. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Nov 01; 120(18):3783-92. PMID: 22968454; PMCID: PMC3488890.
      Citations: 51     Fields:    Translation:HumansAnimals
    50. Hoeller S, Zhou Y, Kanagal-Shamanna R, Xu-Monette ZY, Hoehn D, Bihl M, Swerdlow SH, Rosenwald A, Ott G, Said J, Dunphy CH, Bueso-Ramos CE, Lin P, Wang M, Miranda RN, Tzankov A, Medeiros LJ, Young KH. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol. 2013 Jan; 44(1):110-21. PMID: 22944294; PMCID: PMC3640316.
      Citations: 9     Fields:    Translation:Humans
    51. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012 Oct 18; 120(16):3260-70. PMID: 22932796; PMCID: PMC3476538.
      Citations: 88     Fields:    Translation:HumansAnimalsCells
    52. Chen Z, Romaguera J, Wang M, Fayad L, Kwak LW, McCarty N. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br J Haematol. 2012 Oct; 159(2):243-6. PMID: 22924544; PMCID: PMC3460105.
      Citations: 3     Fields:    Translation:HumansCells
    53. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48. PMID: 22845873; PMCID: PMC5818209.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    54. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 04; 120(14):2817-25. PMID: 22833546; PMCID: PMC4123387.
      Citations: 247     Fields:    Translation:HumansCTClinical Trials
    55. Zhang KJ, Liang R, Wang LH. [Research focus on multiple myeloma at the 53rd American Society of Hematology meeting]. Zhonghua Xue Ye Xue Za Zhi. 2012 Jul; 33(7):596-8. PMID: 22967431.
      Citations:    Fields:    Translation:Humans
    56. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23. PMID: 22677155.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    57. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70. PMID: 22555973; PMCID: PMC4123327.
      Citations: 102     Fields:    Translation:HumansCTClinical Trials
    58. Liu X, Guo W, Wu S, Wang L, Wang J, Dai B, Kim ES, Heymach JV, Wang M, Girard L, Minna J, Roth JA, Swisher SG, Fang B. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol. 2012 May 15; 83(10):1456-64. PMID: 22387047; PMCID: PMC3391570.
      Citations: 20     Fields:    Translation:HumansCells
    59. Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Blood. 2012 Mar 15; 119(11):2568-78. PMID: 22294726; PMCID: PMC3311276.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    60. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6. PMID: 22231283; PMCID: PMC3894831.
      Citations: 10     Fields:    Translation:Humans
    61. Papathomas TG, Venizelos I, Dunphy CH, Said JW, Wang ML, Campo E, Swerdlow SH, Chan JC, Bueso-Ramos CE, Weisenburger DD, Medeiros LJ, Young KH. Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Hum Pathol. 2012 Apr; 43(4):467-80. PMID: 22221705.
      Citations:    Fields:    Translation:Humans
    62. Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, Kwak L, Rustveld L, Du XL, Wang M. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012 Aug 01; 118(15):3793-800. PMID: 22139816.
      Citations: 30     Fields:    Translation:HumansPHPublic Health
    63. Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N. Bortezomib-resistant nuclear factor ?B expression in stem-like cells in mantle cell lymphoma. Exp Hematol. 2012 Feb; 40(2):107-18.e2. PMID: 22024108; PMCID: PMC3398482.
      Citations: 13     Fields:    Translation:HumansCells
    64. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5. PMID: 22015451; PMCID: PMC4110463.
      Citations: 21     Fields:    Translation:Humans
    65. Sun L, Zhang L, Qian J, Yang J, Yi Q, Dong W, Wang M. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res. 2012 Mar; 36(3):363-8. PMID: 22000823.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    66. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15. PMID: 21887685; PMCID: PMC4015116.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    67. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22. PMID: 21780997.
      Citations: 30     Fields:    Translation:Humans
    68. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood. 2011 Oct 13; 118(15):4140-9. PMID: 21844567; PMCID: PMC3204731.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    69. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res. 2011 Sep 15; 17(18):5945-52. PMID: 21813633; PMCID: PMC3176952.
      Citations: 6     Fields:    Translation:HumansCells
    70. Tan CH, Wang M, Fu WJ, Vikram R. Nodular extramedullary multiple myeloma: hepatic involvement presenting as hypervascular lesions on CT. Ann Acad Med Singap. 2011 Jul; 40(7):329-31. PMID: 21870026.
      Citations: 3     Fields:    Translation:Humans
    71. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7. PMID: 21477075.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    72. Cao Y, Lan Y, Qian J, Zheng Y, Hong S, Li H, Wang M, Kwak LW, Lin D, Yang J, Yi Q. Targeting cell surface ?2 -microglobulin by pentameric IgM antibodies. Br J Haematol. 2011 Jul; 154(1):111-21. PMID: 21554263; PMCID: PMC3111817.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    73. Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011 Mar 26; 71(5):625-49. PMID: 21443285.
      Citations: 10     Fields:    Translation:HumansAnimals
    74. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011 Mar; 152(5):579-92. PMID: 21241278; PMCID: PMC3402914.
      Citations: 29     Fields:    Translation:HumansCells
    75. Bao H, Lu P, Li Y, Wang L, Li H, He D, Yang Y, Zhao Y, Yang L, Wang M, Yi Q, Cai Z. Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biol Ther. 2011 Jan 01; 11(1):58-67. PMID: 21248470.
      Citations: 15     Fields:    Translation:HumansCells
    76. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011 Apr 01; 286(13):11009-20. PMID: 21189262; PMCID: PMC3064156.
      Citations: 63     Fields:    Translation:HumansCells
    77. Wen J, Feng Y, Bjorklund CC, Wang M, Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, Chang CC. Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther. 2011 Jan; 10(1):148-58. PMID: 21062912.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    78. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene. 2011 Mar 17; 30(11):1329-40. PMID: 21057542; PMCID: PMC4128235.
      Citations: 23     Fields:    Translation:HumansCells
    79. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011 Mar; 35(3):380-6. PMID: 21047686.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    80. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2445-52. PMID: 20805315; PMCID: PMC2966770.
      Citations: 26     Fields:    Translation:HumansCells
    81. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res. 2010 Nov; 5(3):212-25. PMID: 20851072; PMCID: PMC2952723.
      Citations: 13     Fields:    Translation:HumansAnimals
    82. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Oct; 151(1):47-53. PMID: 20735402.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    83. Ross WA, Egwim CI, Wallace MJ, Wang M, Madoff DC, Lee JH. Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Dig Dis Sci. 2010 Nov; 55(11):3271-7. PMID: 20632106.
      Citations: 5     Fields:    Translation:Humans
    84. Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MH. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2011 Apr; 46(4):510-5. PMID: 20581887; PMCID: PMC4080410.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    85. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Jul; 150(2):200-8. PMID: 20528872.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    86. Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM, Harousseau JL. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010 Oct; 95(10):1738-44. PMID: 20460639; PMCID: PMC2948100.
      Citations: 33     Fields:    Translation:Humans
    87. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology. 2010 Apr; 15(2):70-3. PMID: 20423566.
      Citations: 10     Fields:    Translation:Humans
    88. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1122-9. PMID: 20178853; PMCID: PMC3414196.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    89. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 01; 27(31):5213-8. PMID: 19770379.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    90. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009 Sep; 84(9):553-9. PMID: 19565649.
      Citations: 57     Fields:    Translation:HumansAnimalsCells
    91. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009 Oct 22; 114(17):3625-8. PMID: 19710503; PMCID: PMC2766678.
      Citations: 138     Fields:    Translation:HumansCells
    92. Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood. 2009 Oct 29; 114(18):3880-9. PMID: 19654406; PMCID: PMC2773487.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    93. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 2010 Mar; 45(3):498-504. PMID: 19633690; PMCID: PMC5777472.
      Citations: 22     Fields:    Translation:Humans
    94. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, Papalardo E, Vargas G, Deora AB, Wang M, Jacovina AT, Garcia-Latorre E, Reyes-Maldonado E, Hajjar KA, Pierangeli SS. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009 Oct 01; 114(14):3074-83. PMID: 19628708; PMCID: PMC6055708.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    95. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jul; 15(7):812-6. PMID: 19539212; PMCID: PMC4112358.
      Citations: 17     Fields:    Translation:HumansAnimalsCTClinical Trials
    96. Zhou Y, Garcia MK, Chang DZ, Chiang J, Lu J, Yi Q, Romaguera J, Delasalle K, Guo Y, Forman A, Fang W, Wang M. Multiple myeloma, painful neuropathy, acupuncture? Am J Clin Oncol. 2009 Jun; 32(3):319-25. PMID: 19887992.
      Citations: 9     Fields:    Translation:HumansAnimals
    97. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S, K?rbling M. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23. PMID: 19450756; PMCID: PMC4352933.
      Citations: 39     Fields:    Translation:Humans
    98. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, Cai Z, Yi Q. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009 Jul; 23(7):1320-8. PMID: 19225534; PMCID: PMC5890427.
      Citations: 13     Fields:    Translation:HumansCells
    99. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008 Dec; 14(12):1401-7. PMID: 19041063; PMCID: PMC4112362.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    100. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer. 2008 Dec 01; 113(11):3231-41. PMID: 18937267; PMCID: PMC6296219.
      Citations: 37     Fields:    Translation:Humans
    101. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008 Nov 15; 113(10):2734-41. PMID: 18973182.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    102. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008 Dec 01; 112(12):4445-51. PMID: 18799726.
      Citations: 53     Fields:    Translation:Humans
    103. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL, Wang M. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008 Aug 15; 113(4):791-8. PMID: 18615506.
      Citations: 88     Fields:    Translation:Humans
    104. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res. 2008 Apr 01; 14(7):2154-60. PMID: 18381957.
      Citations: 13     Fields:    Translation:HumansAnimals
    105. Ke XY, Wang YF, Yang YH, Wang LH. [Multiple myeloma: past, present and future--editorial]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Apr; 16(2):231-9. PMID: 18426640.
      Citations:    Fields:    Translation:Humans
    106. Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, Kwak L, Yi Q, Wang M. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol. 2008 Feb; 83(2):144-9. PMID: 17722077.
      Citations: 6     Fields:    Translation:HumansCells
    107. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22; 357(21):2133-42. PMID: 18032763.
      Citations: 362     Fields:    Translation:HumansCTClinical Trials
    108. Hou J, Wang M. Current status and future directions in the treatment of multiple myeloma. Chin Med J (Engl). 2007 Oct 05; 120(19):1651-4. PMID: 17935663.
      Citations:    Fields:    Translation:Humans
    109. Rohatgi N, Du XL, Coker AL, Moye LA, Wang M, Fang S. Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort. Am J Clin Oncol. 2007 Oct; 30(5):540-8. PMID: 17921717.
      Citations: 5     Fields:    Translation:Humans
    110. Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PMID: 18000495.
      Citations: 1     Fields:    Translation:Humans
    111. Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, Kwak LW, Romaguera J, Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan; 22(1):179-85. PMID: 17898787.
      Citations: 29     Fields:    Translation:Animals
    112. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell. 2007 Sep; 12(3):252-65. PMID: 17785206.
      Citations: 52     Fields:    Translation:HumansAnimalsCells
    113. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007 Oct 15; 110(8):3028-35. PMID: 17644731; PMCID: PMC2018676.
      Citations: 21     Fields:    Translation:HumansCells
    114. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1066-72. PMID: 17697969.
      Citations: 13     Fields:    Translation:HumansCells
    115. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5. PMID: 17608763.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    116. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007 Jun; 12(3):235-9. PMID: 17558699.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    117. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 01; 110(5):1587-94. PMID: 17515399; PMCID: PMC1975842.
      Citations: 53     Fields:    Translation:HumansAnimalsCellsPHPublic HealthCTClinical Trials
    118. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007 Jun 15; 109(12):5455-62. PMID: 17317853.
      Citations: 16     Fields:    Translation:AnimalsCells
    119. Mullen EC, Wang M. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clin J Oncol Nurs. 2007 Feb; 11(1):87-95. PMID: 17441400.
      Citations: 1     Fields:    Translation:Humans
    120. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007 Mar; 39(5):279-83. PMID: 17262062.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    121. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006 Nov 15; 194(10):1394-7. PMID: 17054068.
      Citations: 13     Fields:    Translation:HumansCells
    122. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006 Oct; 10(4):295-307. PMID: 17045207.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    123. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer. 2006 Nov; 42(17):2976-81. PMID: 17008093.
      Citations: 5     Fields:    Translation:Humans
    124. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2006 Jul; 6(7):983-91. PMID: 16831071.
      Citations: 1     Fields:    Translation:Humans
    125. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 01; 23(28):7013-23. PMID: 16145068.
      Citations: 133     Fields:    Translation:HumansCTClinical Trials
    126. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer. 2005 Jul 11; 93(1):70-80. PMID: 15970928; PMCID: PMC2361492.
      Citations: 31     Fields:    Translation:HumansCells
    127. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol. 2005 Jul; 79(3):194-7. PMID: 15981221.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    128. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 01; 23(4):667-75. PMID: 15613697.
      Citations: 122     Fields:    Translation:HumansCTClinical Trials
    129. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004 Oct 01; 101(7):1508-13. PMID: 15378497.
      Citations: 7     Fields:    Translation:Humans
    130. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102. PMID: 15353540.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    131. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol. 2003 Oct; 40(4 Suppl 4):3-7. PMID: 15015890.
      Citations: 3     Fields:    Translation:Humans
    132. Wang ML, Younes A. Testicular lymphoma: a mysterious link between the testis and the brain. Clin Lymphoma. 2002 Dec; 3(3):173-4. PMID: 12521395.
      Citations:    Fields:    Translation:Humans
    133. Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol. 2001 Aug; 24(4):421-4. PMID: 11474279.
      Citations: 18     Fields:    Translation:Humans
    134. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res. 1999 Jan 01; 59(1):14-8. PMID: 9892176.
      Citations: 20     Fields:    Translation:AnimalsCells
    135. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology.
    136. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology.
    137. Immunotherapy for mantle cell lymphoma. Journal of Leukemia and Lymphoma. 17.
    138. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9.
    139. CD4+ T cells play a crucial role for lenalidomide in vivo antitumor activity in murine multiple myeloma. Oncotarget. 6:36032-36040.
    140. Dominant negative signal transducer and activator of transcription 2 (STAT2) protein. Molecular Cancer Therapeutics. 2:453-459.
    141. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27:1317-1323.
    142. Elotuzumab for the treatment of multiple myeloma. Journal of Hematology and Oncology. 9.
    143. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology. 27:895-901.
    144. Potential effects of CRM1 inhibition in mantle cell lymphoma. Chinese Journal of Cancer Research. 24:374-387.
    145. Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget. 7:58638-58648.
    146. Abnormal serum protein electrophoresis. Unknown Journal. 264-267.
    147. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. British Journal of Haematology.
    148. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 7:3548-3558.
    149. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma. British Journal of Haematology.
    150. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 128:1688-1700.
    151. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors. Archiv der Pharmazie. 349:356-362.
    152. Targeting the spleen tyrosine kinase with fostamatinib as a strategy against Waldenström Macroglobulinemia. Clinical Cancer Research. 21:2538-2545.
    153. Lenalidomide in relapsed or refractory mantle cell lymphoma. Therapeutic Advances in Hematology. 5:91-101.
    154. Daratumumab. Journal of Hematology and Oncology. 9.
    155. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia.
    156. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma. The Lancet Oncology.
    157. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Annals of Oncology. 27:778-787.
    158. New kid on the block. Cell Cycle. 14:3526.
    159. Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. Oncotarget. 6:345-354.
    160. Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chloniakiem z komórek plaszcza - Wyniki miedzynarodowego, wieloosrodkowego, badania II fazy z ibrutynibem (PCI-32765) - EHA Encore. Acta Haematologica Polonica. 44:314-318.
    161. Reply [6]. American Journal of Hematology. 81:386.
    162. Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. Leukemia and Lymphoma. 1-3.
    163. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology.
    164. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma. British Journal of Haematology. 175:290-299.
    165. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. Journal of Hematology and Oncology. 8.
    166. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 7:73558-73572.
    167. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 7:74380-74392.
    168. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference. Leukemia and Lymphoma. 1-5.
    169. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 128:1174-1180.
    WANG's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (539)
    Co-Authors (122)
    Similar People (60)
    Same Department Expand Description